Amello Jason 4

What Happened

• Jason Amello, Chief Financial Officer of TScan Therapeutics (TCRX), was granted a 350,000-share award on January 20, 2026. The Form 4 lists the transaction as a derivative award (code A) with an indicated acquisition price of $0.00, reflecting a stock option-type grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-20; Form 4 filed: 2026-01-22 (timely filing).
• Transaction type/code: Grant/Award (derivative); amount: 350,000 shares; price shown: $0.00 (typical for option grants on Form 4).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote (vesting): 25% vests on the one-year anniversary of Jan 20, 2026, then the remaining balance vests in equal monthly installments over the following 36 months, subject to continued service.
• No 10b5-1 plan, tax-withholding sale, or sale activity reported in this filing.

Context

• This is a compensation award (stock option-type grant) rather than a market purchase or sale. The options are subject to multi-year vesting and are not described as immediately exercised or sold, so there is no immediate change in marketable shares.
• Such grants are common for executive compensation and should be viewed as part of pay structure rather than a direct bullish or bearish trading signal.